dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Steinhoff, Bernhard |
dc.contributor.author | Ben-Menachem, Elinor |
dc.contributor.author | Brandt, Christian |
dc.contributor.author | García Morales, Irene |
dc.contributor.author | Rosenfeld, William |
dc.contributor.author | Santamarina Pérez, Estevo |
dc.contributor.author | Serratosa, José M. |
dc.date.accessioned | 2022-09-09T12:55:28Z |
dc.date.available | 2022-09-09T12:55:28Z |
dc.date.issued | 2022-09 |
dc.identifier.citation | Steinhoff BJ, Ben-Menachem E, Brandt C, García Morales I, Rosenfeld WE, Santamarina E, et al. Onset of efficacy and adverse events during Cenobamate titration period. Acta Neurol Scand. 2022 Sep;146(3):265–75. |
dc.identifier.issn | 1600-0404 |
dc.identifier.uri | https://hdl.handle.net/11351/8121 |
dc.description | Cenobamat; Epilèpsia resistent a medicaments; Convulsions |
dc.description.sponsorship | The double-blind studies and open-label study were funded by SK Life Science, Inc. (Paramus, NJ, USA). Study data were pooled and analyzed by Angelini S.p.a. Nicole Day, PhD, of MedVal Scientific Information Services, LLC (Princeton, NJ, USA) provided medical writing assistance, funded by Angelini S.p.a. The manuscript was prepared according to the International Society for Medical Publication Professionals' “Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.” |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Acta Neurologica Scandinavica;146(3) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Epilèpsia - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Anticonvulsius - Efectes secundaris |
dc.subject.mesh | Anticonvulsants |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Epilepsy |
dc.subject.mesh | Treatment Outcome |
dc.title | Onset of efficacy and adverse events during Cenobamate titration period |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/ane.13659 |
dc.subject.decs | anticonvulsivantes |
dc.subject.decs | /efectos adversos |
dc.subject.decs | epilepsia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1111/ane.13659 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Steinhoff BJ] Department for Adults, Kork Epilepsy Center, Kehl-Kork, Germany. Department of Neurology and Clinical Neurophysiology and Medical Faculty, University of Freiburg, Freiburg, Germany. [Ben-Menachem E] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. [Brandt C] Department of General Epileptology, Bethel Epilepsy Centre, Mara Hospital, University Hospital for Epileptology, Bielefeld, Germany. [García Morales I] Servicio de Neurología, Programa de Epilepsia, Hospital Ruber Internacional, Madrid, Spain. [Rosenfeld WE] Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, Missouri, USA. [Santamarina E] Unitat d’Epilèpsia, Servei de Neurologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Serratosa JM] Epilepsy Unit, Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain |
dc.identifier.pmid | 35711112 |
dc.identifier.wos | 000811891300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |